Wednesday, May 6, 2015

Adaptive Biotechnologies Finds $195M

Seattle-based Adaptive Biotechonlogies, a developer of high throughput genetic sequencing technology, said Wednesday that it has raised $195M in a funding round. The company said the funding came from Matrix Capital Management, and also included Senator Investment Group, Tiger Management, Rock Springs Capital and an un-named, additional large healthcare investor, plus Viking Global, Casdin Capital and Alexandria Real Estate Equities and other strategic investors. Adaptive, which is led by Chad Robins, said the funds will go towards regulatory approvals of its molecular diagnostics process. More information »